ESP Pharma Report issue

For profit
Founded: Edison NJ United States (2002)
Status: Acquired by PDL BioPharma (2005) → now Abbott (2010)

Organization Overview

First Clinical Trial
2006
NCT00363467
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Other Trials (3)

busulfan (myleran) (1 trial)

sargramostim (leukine) (1 trial)

stem cells (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 3